GlassScriptPhysician profile
Deborah Ball Fallon
NPI 1639243561
$24,931.35
in general payments reported to CMS, 2019-2025
25 companies · $4,797 in 2025
The $4,797 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,325 · 2022: $4,668 · 2023: $5,692 · 2024: $5,450 · 2025: $4,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $82.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,856.45 |
| Education | $82.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,520.61 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $3,299.29 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,180.16 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,844.48 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $2,348.19 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $2,110.99 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $1,961.62 | 2021-2022 | |
| Alkermes, INC. | $1,417.28 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $990.99 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $883.81 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $501.72 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $355.90 | 2023-2025 | Auvelity |
| Bausch Health US, LLC | $344.36 | 2021-2025 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $341.37 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $185.66 | 2022-2024 | Loreev Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $123.50 | 2021 | |
| Merck Sharp & Dohme LLC | $88.98 | 2021-2022 | |
| Indivior INC. | $84.63 | 2021-2024 | Perseris |
| Eisai INC. | $84.60 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.02 | 2023 | |
| Supernus Pharmaceuticals, INC. | $46.79 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $42.17 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $39.52 | 2021-2022 | |
| Luye Pharma (USA) LTD. | $36.07 | 2025 | Erzofri Extended-Release |
| Alfasigma USA, INC. | $21.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Fallon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.